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To the Editor:
We read with keen interest the 
article by Chiu et al1 on the clinical 
characteristics and treatment outcomes 
of patients with lung adenocarcino-
mas with discrepant EGFR mutation 
testing results by polymerase chain 
reaction (PCR)-direct sequencing and 
the more sensitive mutant allele-spe-
cific real-time PCR-based Scorpion 
Amplification Refractory Mutation 
System (ARMS) which showed that 
21.5% of 130 tumours which were 
EGFR mutation-negative by direct 
sequencing were found to have EGFR 
mutations by the latter assay.
patients), and Indian (33.3% of 39 
patients) patients. Our study was the 
first report on the prevalence of EGFR 
mutation in patients of Malay ethnicity 
that was not covered by the PIONEER 
study. The Malays constitute a sizeable 
population in Southeast Asia includ-
ing Malaysia, Indonesia, parts of the 
Philippines, and parts of Thailand.
We could have overestimated the 
frequency of EGFR mutations in our 
patients of Indian ethnicity because of 
the small number of Indian patients 
compared with the PIONEER study1 
with 73 patients of Indian ethnicity and a 
study in India3 where 23% of adenocar-
cinomas from 907 patients were EGFR 
mutation positive. The frequency of 
EGFR mutation among Indian patients 
with adenocarcinoma in the PIONEER 
study1 and the study in India3 which is 
intermediate between that of East Asian 
patients (approximately 50–64%)1 and 
Western patients (approximately 20%)4 
is probably because of an admixture of 
genetic influence from Middle Eastern, 
Central Asian, and European ancestors 
on the modern-day Indian population 
that may confer differential susceptibil-
ity to somatic mutations in EGFR.5
Similar to the findings by the 
PIONEER study,1 EGFR mutations 
were significantly more frequent among 
our female than in male patients (52.5% 
versus 27.8%) and in our patients who 
had never smoked compared with those 
who had smoked (54.8% versus 20.7%).2 
We also observed that a never smoking 
status was the independent predictor of 
EGFR mutation positivity and female 
gender was not a significant predictor 
after adjusting for smoking status.2
We concur with Shi et al1 that the 
observed high frequency of EGFR muta-
tions in Asian patients including those of 
Indian ethnicity compared with Caucasian 
populations suggests that mutation test-
ing should be considered for all Asian 
patients with advanced lung adenocarci-
noma, even in males and smokers.
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In our study involving 812 
patients with lung adenocarcinoma 
from 2009 to 2011,2 bidirectional 
sequencing3,4 was initially used to 
detect EGFR mutations in formalin-
fixed, paraffin-embedded tumour 
biopsy specimens from November 2009 
to August 2011 but the method was 
later switched to real-time PCR (EGFR 
RGQ PCR Kit; QIAGEN, Manchester, 
United Kingdom). The bidirectional 
sequencing method used primers and 
PCR conditions as described by Lynch 
et al.3 Uncloned PCR fragments were 
purified and subjected to sequencing 
before being analyzed for the presence 
of mutation in both sense and antisense 
directions. In real-time-PCR, mutations 
of EGFR (exons 18, 19, 20, and 21) 
genes were detected by ARMS prim-
ers and Scorpion detection technology 
on Rotor-Gene platform (QIAGEN). 
The direct sequencing method was used 
for EGFR mutation detection in 416 
(51.2%) of our tumor samples. A higher 
percentage of tumours were tested 
EGFR mutation-positive by Scorpion 
ARMS (170 [42.9%] of 396 tumours) 
than by direct sequencing (151 [36.3%] 
of 416 tumours) but the difference was 
not statistically significant (p = 0.053). 
However, although we did not perform 
a head-to-head comparison of the two 
methods, our results also suggested 
that allele-specific, real-time PCR was 
more sensitive than direct sequencing 
in detecting EGFR mutations, and this 
may partly explain the lower EGFR 
mutation frequency of 39.5% in our 
patients with adenocarcinoma com-
pared with other East Asian ethnici-
ties (Vietnamese, 64.2%; Thai, 53.8%; 
Chinese, 51.8%, and Filipino, 50.0%) as 
shown by the PIONEER study in which 
Scorpion ARMS was used.5 In our 
study, exon 19 mutations (in 23.5% of 
tumours) were the most common muta-
tions followed by exon 21 mutations (in 
14.9% of tumours).2 Interestingly, exon 
19 mutations were significantly more 
frequently detected by Scorpion ARMS 
(108 [27.3%] of 396 tumours) than by 
direct sequencing (83 [20.0%] of 416 
tumours; p = 0.018) in our study.2
We agree with Chiu et al1 that 
direct sequencing may under-detect 
EGFR mutations in a significant propor-
tions of lung adenocarcinoma patients 
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in East Asia, a region with a high EGFR 
mutation prevalence and hence, may 
deprive such patients with false-negative 
results of first-line EGFR tyrosine kinase 
inhibitor treatment which its attendant 
better overall response rate and longer 
progression-free survival compared with 
first-line cytotoxic chemotherapy.
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